1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Brenig Therapeutics Raises $65 Million in Series A Funding to Advance Pre-Clinical Pipeline

25 Jul 2024
Admin
News Article

Brenig Therapeutics Raises $65 Million in Series A Funding to Advance Pre-Clinical Pipeline

Brenig Therapeutics Raises $65 Million in Series A Funding to Advance Pre-Clinical Pipeline for Parkinson’s Disease

Overview

Brenig Therapeutics Inc., a trailblazer in neurology-focused drug development utilizing an AI/ML-based discovery platform, has successfully completed a $65 million Series A funding round. The round was led by New Enterprise Associates (NEA), with participation from another US-based healthcare investor and existing investors including OrbiMed, Torrey Pines Investments, and BioGeneration Ventures. Ed Mathers, Partner at NEA, will join the company’s Board of Directors as part of this investment.

Words from Chairman: Brenig

Iain Dukes MA DPhil, Chairman of Brenig, commented on the funding: "This capital will help us advance our mission to develop therapies for Parkinson’s disease that stand out in the field."

Words from Ed Mathers

Ed Mathers highlighted the progress made by Brenig, stating, "The team at Brenig has made significant strides since its start. We are confident that their approach could lead to superior treatments for Parkinson’s disease. NEA is excited to support Brenig as it enters this next stage of development."

About Funds

The funds will be allocated to progressing BT-267 through studies with healthy volunteers and into proof-of-concept trials in idiopathic Parkinson's disease patients. Brenig also plans to explore further innovative approaches for treating Parkinson’s disease.

About BT-267

BT-267 is a small molecule LRRK2 inhibitor designed for optimal pharmacokinetic performance, ensuring high and sustained brain exposure with minimal peripheral exposure.
This aims to enhance therapeutic efficacy while reducing on-target, off-tissue toxicity.
The molecule displays exceptional kinome selectivity, avoiding off-target effects, and has demonstrated a favorable safety profile in ongoing GLP studies.